This 1-year, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of zonisamide, an antiepileptic drug, for weight reduction in 225 obese adults (mean BMI 37.6 kg/m²) without diabetes. Participants received daily doses of placebo, 200 mg zonisamide, or 400 mg zonisamide, alongside diet and lifestyle counseling. At 12 months,
This 1962 study by Le Riche and Van Belle evaluated the efficacy and safety of phendimetrazine bitartrate as an appetite suppressant in obese patients. Participants received varying doses of phendimetrazine, and outcomes were assessed in terms of weight loss and side effects. The study found that phendimetrazine effectively suppressed appetite
This systematic review evaluates the health benefits and safety of resveratrol, a polyphenolic compound found in plants, based on over 244 clinical trials. Resveratrol has shown promise in improving outcomes for a variety of chronic conditions, including diabetes, obesity, certain cancers, metabolic syndrome, hypertension, Alzheimer’s disease, stroke, cardiovascular diseases, kidney
This review examines the dual effects of resveratrol on anxiety and stress disorders, highlighting its potential to alleviate anxiety through mechanisms such as antioxidant activity, mitochondrial function enhancement, and neuroplasticity improvement. However, it also emphasizes that under certain conditions, resveratrol may exacerbate anxiety symptoms, suggesting a need for careful dosage
The study titled “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study” was published in the Journal of Urology in 1998 (PMID: 9679884). This double-blind, placebo-controlled crossover study investigated the effects of Melanotan-II, a synthetic melanotropic peptide, on men with psychogenic erectile dysfunction.
This randomized controlled trial evaluated the effects of Melanotan II, a melanocortin receptor agonist, on penile erection and sexual desire in men with psychogenic and organic erectile dysfunction (ED). Among 20 participants, 85% experienced spontaneous penile erections without sexual stimulation, and 68% reported increased sexual desire after Melanotan II administration,
This meta-analysis examined the relationship between menopausal estrogen replacement therapy (ERT) and breast cancer risk, showing that low-dose estrogen (0.625 mg/day or less) did not significantly increase breast cancer risk, while higher doses (1.25 mg/day or more) were associated with a higher risk, though with some variability in risk estimates.
